Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 69Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 48Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 35Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Biliary Tract Neoplasms 29Neoplasms 28Neoplasm Metastasis 28Cholangiocarcinoma 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Ovarian Neoplasms 24Liver Neoplasms 18Head and Neck Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 14Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

Tenofovir 3peginterferon alfa-2b 2peginterferon alfa-2a 1ibrutinib 1entecavir 1durvalumab 1babao dan 1Radiofrequency Ablation 1Cholecalciferol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hepatitis B, Chronic × durvalumab × Clear all
NCT04294498 2025-03-26

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

National Taiwan University Hospital

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis B, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡